Scholar Rock Holding Corporation shares surge 15.64% intraday after FDA grants priority review to apitegromab for SMA treatment and grants stock awards to new employees.

Wednesday, Aug 20, 2025 11:49 am ET1min read
Scholar Rock Holding Corporation surged 15.64% intraday, following the announcement of stock awards to 64 new employees and FDA's priority review for apitegromab treatment for SMA, with plans to expand in Europe.

Scholar Rock Holding Corporation shares surge 15.64% intraday after FDA grants priority review to apitegromab for SMA treatment and grants stock awards to new employees.

Comments



Add a public comment...
No comments

No comments yet